Trillium Therapeutics Inc (TRIL)

[LongRun8]

TRIL rose 2.7% after a Nasdaq delisting notice indicated that the sale to Pfizer (NYSE:PFE) was tentatively scheduled to close prior to market open tomorrow. The stock is expected to be halted this evening, according to the notice. In late August Pfizer agreed to buy Trillium, a clinical stage immuno-oncology company, in a $2.3B deal. Under the terms of the agreement, Pfizer agreed to buy Trillium for an implied $18.50/share, in cash. The delisting notices comes as Trillium's HSR deadline for the Pfizer deal was scheduled to expire. Trillium didn't immediately return Seeking Alpha request for comment on the status of HSR. Last week, Trillium Therapeutics (TRIL) receives final court order approving arrangement.

From Seeking Alpha